| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Lawson Health Research Institute, St. Joseph’s Health Care (S.T., E.A., D.J.H.), and Departments of Medicine (E.A., D.J.H.), Physiology and Pharmacology (D.J.H.), and Pediatrics (D.J.H.), University of Western Ontario, London, Ontario, Canada N6A 4V2
Address all correspondence and requests for reprints to: Dr. David J Hill, Lawson Health Research Institute, St. Joseph’s Health Care, 268 Grosvenor Street, London, Ontario, Canada N6A 4V2. E-mail: dhill{at}lri.sjhc.london.on.ca.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-cell hyperplasia. These were associated with increased pancreatic content and circulating levels of glucagon. Pancreatic levels of glucagon-like polypeptide-1 (GLP-1) were increased 8 d after STZ compared with control values, and the GLP-1/glucagon ratio changed in favor of GLP-1. Administration of a GLP-1 receptor antagonist, GLP-1-(9–39), resulted in decreased recovery of ß-cells after STZ and worse glucose tolerance. Atypical glucagon-positive cells were found within islets that colocalized pancreatic duodenal homeobox-1 or glucose transporter-2. Pancreatic levels of insulin mRNA did not return to control values until 40 d after STZ. Insulin-positive cells were found after 8 d that colocalized glucagon and GLP-1. The model shows that the pancreas of the young rat can rapidly regenerate a loss of ß-cells, and this is associated with hyperplasia of -cells with an altered phenotype of increased GLP-1 synthesis. The target cells of GLP-1 probably include immature ß-cells that coexpress proglucagon. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Although the embryonic origins and development of islets of Langerhans have been extensively studied (5, 6, 7), it is not clear whether regeneration postnatally involves a recapitulation of these pathways or whether ß-cells derive from different precursor populations. We and others have shown that the endocrine pancreas in the rat undergoes substantial remodeling between 1 and 4 wk of fetal life, involving a loss of ß-cells due to developmental apoptosis and their replacement with newly derived ß-cells, demonstrating a more mature phenotype of acute, glucose-sensitive insulin release (8, 9). We hypothesized that this period of natural developmental plasticity of ß-cells would allow the identification of mechanisms for ß-cell replacement after depletion with streptozotocin (STZ).
Islet cell development in the embryo occurs from the pancreatic duct epithelium and involves a sequence of expression of transcription factors, including pancreatic duodenal homeobox-1 (Pdx-1), neurogenin-3, and Nkx2.2 (5, 6). Differentiation of lineages leading to ß- and -cells is determined by the differential expression of Pax (paired box) 4 vs. Pax6. The exact nature of the endocrine embryological cell precursor in the pancreas is uncertain, although is appears to be neurogenin-3-positive (10, 11). Cells immunopositive for nestin and c-Kit are located adjacent to pancreatic ducts and within islets (12). Although these were originally thought to be endocrine cell precursors, they were subsequently shown through lineage tracing to be mesenchymal and more closely associated with endothelial cell formation and vascular remodeling (13, 14). However, they appear intimately connected to endocrine cell development. Herrera (15) used cell-targeted diphtheria toxin expression to specifically delete glucagon-, insulin-, and pancreatic polypeptide-expressing cells, and concluded that glucagon-positive cells were not precursors for ß-cells. Studies with Cre-tagged cells showed that insulin- and glucagon-expressing cells derive from mutually exclusive cell populations, but both can derive from Pdx-1-positive cells (15, 16). Both insulin and glucagon precursors can express the pancreatic polypeptide gene, but somatostatin and insulin share more immediate precursors than either do with glucagon (17).
Despite an 8-fold increase in ß-cell mass between 1 month of age and adulthood in the rat, the endogenous rate of DNA synthesis falls 5-fold by 3 months of age (18). Renewal of ß-cells postnatally potentially originates from several sources. Increased ß-cell mass after prolonged experimental hyperglycemia resulted from tubular foci of new islet development and the frequent appearance of individual insulin-positive cells within acinar tissue, suggestive of cellular transdifferentiation (19). Destruction of acinar tissue after pancreatic duct ligation results in hyperplasia of the pancreatic ducts and the appearance of new islets by neogenesis (20). After partial pancreatectomy, there is partial compensation by the expansion of remaining islets through either ß-cell replication or the activation and differentiation of endogenous precursor cells (21). The model of STZ depletion of ß-cells in the neonatal rat has been studied extensively (22, 23, 24) and has been shown to result in substantial ß-cell replacement, although the animals are predisposed to glucose intolerance later in life. Near-complete removal of ß-cells leads to partial replacement through the appearance of new islets, whereas subtotal destruction is followed by renewal from within the islets (17, 22, 23, 24, 25). Cell lineage marking of ß-cells in mice followed by partial pancreatectomy showed that new ß-cells in the remaining organ derived almost exclusively from existing ß-cells in adult life (26). However, there is also clear evidence of a scarce subpopulation of multipotent islet precursor cells resident in both ducts and islets of the adult mouse pancreas (27). We have used partial deletion of ß-cells with STZ in the neonatal rat to better define the mechanisms by which regeneration of ß-cells can occur in early life.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Animals
Timed pregnant Wistar rats were purchased from Charles River Laboratories, Inc. (Montréal, Canada) and were delivered to the animal care facility at Lawson Health Research Institute at 17 d gestation to allow for acclimatization before parturition. Access to water and standard rat chow was given ad libitum, and animals were provided with a 12-h dark, 12-h light cycle. Litters were reduced to 12 pups at birth. On d 4 of postnatal life, half the pups in each litter were given a single ip bolus injection of 70 mg/kg STZ (Sigma-Aldrich Corp.) freshly prepared in citrate buffer (pH 4.5). The remainder received a sham injection of vehicle only. In one series of animals, the pups were anesthetized the day after receiving STZ or sham injection with a mixture of ketamine (30 mg/ml) and xylazine (3 mg/ml; 1 µl/g body weight), a microosmotic pump (model 1002; Alzet Corp., Cupertino, CA) was located sc in the dorsal area, and the incision was closed. Pumps were preloaded with 0.182 mg GLP-1-(9–39) in 100 µl saline, which was calculated to release at a rate of 50 pM/kg·min for 2 wk. Control animals received pumps loaded with saline alone. Glucose was monitored daily with a hand-held glucometer DEX-2 (Bayer, Inc., Toronto, Canada) by lancing the tail vein (2 µl blood). Body weight was recorded, and animals were killed every 2 d by decapitation (up to d 6 of age) or by CO2 asphyxiation until d 20, then at 40 d. Animals with minipumps were killed after exhaustion of their contents on d 19. Pancreata were collected immediately and snap-frozen on liquid nitrogen or fixed for histology. Blood was collected, and serum was separated and stored at –20 C. Four to six pups from at least three separate litters were studied at each time point. Some animals receiving osmotic minipumps were subjected to a glucose tolerance test on postnatal d 28. A bolus of ip glucose (2 g/kg weight) was given after a 5-h fast, and blood was sampled from the tail vein for up to 2 h for glucose measurement.
Animal procedures were performed with the approval of the animal care committee of the University of Western Ontario in accordance with the guidelines provided by the Canadian Council for Animal Care.
Immunohistochemistry
Tissue was fixed in 10% neutral buffered formalin for 24–36 h and was embedded in paraffin. Sequential sections of 5 µm were cut and mounted on SuperFrost Plus glass slides (Fisher Scientific, Toronto, Canada). Immunohistochemistry was performed on pancreas sections to localize insulin and glucagon by a modified avidin-biotin peroxidase method (28). All antisera were diluted in 0.1 M PBS (pH 7.5) containing 0.25% (wt/vol) BSA, 0.3% (vol/vol) Triton X-100, and 0.01% (wt/vol) sodium azide (100 µl/slide). Slides were incubated for 24 h in a humidified chamber at 4 C. Biotinylated horse antimouse and goat antirabbit were used as secondary antibodies. Peptide immunoreactivity was localized by incubation in fresh diaminobenzidine tetrahydrochloride (Biogenex, San Ramon, CA). Tissue sections were counterstained with Carazzi’s hematoxylin.
Dual staining for PCNA and glucagon was performed by first incubating with mouse anti-PCNA as described above. Signal amplification and visualization were accomplished by incubation in an avidin-biotin complex solution (Vectastain ABC Elite, Vector Laboratories, Inc., Burlingame, CA) and were visualized using alkaline phosphatase with blue reaction product (alkaline phosphatase substrate kit III, Vector Laboratories, Inc.) as the chromogen. Sections were then subjected to immunohistochemistry for glucagon as described above, using alkaline phosphatase with a red reaction product (Vector Laboratories, Inc.) as the chromogen. Sections were mounted under glass coverslips with an aqueous mounting solution.
For dual immunofluorescent localization of Pdx-1 and glucagon or of Glut-2 and glucagon, sections were deparaffinized and blocked with 10% (vol/vol) goat serum for 1 h at room temperature. After blotting, a mixture containing either rabbit anti-Pdx-1 or rabbit anti-Glut-2 and mouse antiglucagon antibody was added and incubated for 2 h at room temperature. After washing for 10 min in PBS, a mixture of the secondary antibodies, goat antimouse (Alexa 488) and antirabbit (Alexa 555), was added and incubated for 1 h at room temperature. Sections were washed in PBS for 10 min, covered with two or three drops of Prolong Antifade solution (Molecular Probes), and dried at room temperature before examination. GLP-1 and insulin were colocalized as described above by first blocking with 5% (vol/vol) rabbit serum and applying goat anti-GLP-1 antibody, followed by rabbit antigoat (tetramethylrhodamine isothiocyanate) secondary antibody. After 10 min of washing in PBS, the sections were blocked with 5% goat serum, and mouse antiinsulin antibody was applied, followed by goat antimouse (Alexa 488) secondary antibody. Glucagon, insulin, and the GLP-1 receptor were colocalized in a triple-immunofluorescence reaction as described above, except that the primary antiserum was rabbit anti-GLP-1 receptor; mouse antiglucagon and guinea pig antiinsulin were applied simultaneously and were detected with a mixture of goat antirabbit (Alexa 350), antimouse (Alexa 555), and antiguinea pig (Alexa 488) secondary antibodies.
Controls included substitution of primary antisera with nonimmune serum, omission of secondary antiserum, and, for insulin, glucagon, and GLP-1, absence of staining after preincubation of the antiserum with excess antigen. Briefly, the last positive dilution for each antiserum was determined, and the respective peptide was added at 5 times that molar concentration. After overnight incubation at 4 C, the antibody-peptide complex was centrifuged at 4 C at 14,000 rpm for 30 min, and the supernatant was collected. An absence of signal using the supernatant as a first antibody indicated antibody specificity. The supernatant of antiserum without the blocking peptide was also collected as a positive control.
Morphometric analysis
Pancreata from at least three separate litters of rats representing between 12 and 18 animals were examined at each age for sham- and STZ-treated rats. Morphometric analysis was performed for three to five sections, representing different regions of the pancreas, using a transmitted light microscope (Carl Zeiss, Inc., New York, NY) at a magnification of x250, x400, or x1000. Automatic image analysis of pancreatic sections for calculation of tissue areas was performed with Northern Eclipse (version 6.0) morphometric analysis software (Empix Imaging, Mississauga, Canada). The number of small (<5000 µm2), large (>10,000 µm2), or medium (5000–10,000 µm2) islets and the percentage of islet cells immunoreactive for insulin, glucagon, or somatostatin were calculated for each group between 2 and 20 d after treatment. To estimate -cell number, the total number of glucagon-immunoreactive cells per 10 mm2 pancreas was calculated. The number of glucagon- or insulin-positive cells that also showed nuclear staining for PCNA was expressed as a percentage relative to the total number of each cell type within the same sections.
Pancreatic volume-weighted mean islet volumes were calculated as described by Bock et al. (29, 30). Volume-weighted mean islet volume represents the mean volume of islets weighted proportional to their volume and is considered a more accurate estimate than a simple number-weighted mean islet volume (29). This was calculated from:
 |
RNA isolation and RT
Total RNA was isolated from entire frozen pancreas using TRIzol reagent (Invitrogen Life Technologies, Inc., Carlsbad, CA) and was additionally purified using the RNeasy 96-kit (QIAGEN, Valencia, CA) before being resuspended in diethylpyrocarbonate-treated distilled water. RNA concentrations were determined from spectrophotometric absorption at 260 nm, and the ratio of absorbance at 260/280 nm was assessed to confirm purity (ratios >1.9). RT was performed using the Omniscript RT Kit (QIAGEN) following the manufacturer’s instructions. Five micrograms of total RNA were reverse transcribed in a total volume of 50 µl using oligo(deoxythymidine) primers from Sigma-Genosys Corp. (Oakville, Canada). For every RT reaction set, one RNA sample was set up without reverse transcriptase enzyme to provide a negative control. Reactions were incubated at 25 C for 10 min, at 42 C for 50 min, and at 70 C for 15 min. After RT, samples were diluted by adding diethylpyrocarbonate-treated distilled water.
Real-time quantitative RT-PCR
Two different methods of real time PCR were performed. 1) Real-time quantitative PCR was performed using TaqMan probe technologies in an ABI PRISM 7900HT sequence detection system (Applied Biosystems, Foster City, CA) to determine the relative abundance of glucagon (Rn00562293-m1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an endogenous control (TaqMan Rodent GAPDH Control Reagents, P/N: 4308313, Applied Biosystems). These primer probe sets span an intron for RNA specificity. PCRs were run in triplicate 50-µl reactions that contained 25 µl TaqMan Universal PCR Master Mix (P/N 4304437), 2.5 µl 20x Assays-on-Demand Gene Expression Assay Mix (Applied Biosystems), and 150 ng cDNA. Two-step PCR cycling was carried out as follows: one cycle of 50 C for 2 min, one cycle of 95 C 10 min, and 45 cycles of 95 C for 15 sec and 60 C for 1 min. 2) SYBR Green I quantitative real-time PCR was used to study the expression of insulin, GLP-1 receptor, and ß-actin as an endogenous control. Gene-specific primers are shown in Table 1
. All primers were purchased from Sigma-Genosys Corp. SYBR Green I Master Mix (QIAGEN) was used as recommended by the manufacturer [25 µl Master Mix, 2 µl primers (15 µM each), and 400 ng RT product in a total volume of 50 µl in triplicate]. Thermal cycling conditions were 15 min at 95 C, followed by 50 cycles of 15 sec at 95 C, 30 sec at 61.5, and 30 sec at 72 C, followed by a standard dissociation curve. The specificity of the SYBR Green I assay was verified by performing a melting curve analysis and by subsequencing the PCR products. The comparative threshold (CT) method (
CT method) was used, and validation experiments were performed to demonstrate that the efficiencies of target and reference genes were approximately equal (the plot of log input amount vs. CT has a slope < 0.1). The threshold cycle range for proglucagon mRNA was 15–21; that for GAPDH mRNA was 20–28. These varied with the age of animal.
|
Statistical analysis
Data are represented as the mean ± SEM and were compared using Student’s t test or two-way ANOVA to assess the statistical significance between time courses, followed by a Bonferroni posttest when interaction was present. Significance was set at P < 0.05. All calculations were performed using PRISM version 4 (GraphPad, Inc., San Diego, CA) for Windows (Microsoft Corp., Redmond, WA).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
). By d 20 after STZ treatment, blood glucose levels did not differ significantly from those in control rats, which remained euglycemic throughout the study. Treatment with STZ did not significantly alter mean body weight, pancreatic weight (Table 2), or liver weight (data not shown) compared with controls at any time point, and no mortality occurred.
|
|
). Four days after treatment, an increased number of small clusters of insulin-immunoreactive cells were seen adjacent to pancreatic ducts; by d 8, increased numbers of small islets were present without evidence of STZ-induced ß-cell destruction. Between d 20 and 40 after STZ, the larger islets that had originally exhibited ß-cell loss had now remodeled with a uniform core of insulin-positive ß-cells. Calculation of the volume-weighted mean islet volume over the study period in control animals showed a substantial increase between 4 and 8 d (8 and 12 d age), with a decline between d 8 and 20, presumably associated with maturation and expansion of the exocrine tissue compartment. In animals receiving STZ, there was a 66% reduction in mean islet volume vs. controls on d 8 (Fig. 3D). When the percentages of small (<5000 µm2), medium-sized (5000–10,000 µm2), or large (>10,000 µm2) islets were compared, the pancreata from STZ-treated animals had a significantly increased percentage of smaller islets compared with controls on d 8 after treatment, whereas the relative percentage of larger islets was much reduced (Fig. 3, A–C).
|
|
). However, between 8 and 14 d after treatment, the area occupied by glucagon-positive cells increased sharply, as did the presence of somatostatin-containing cells on d 8. Dual immunohistological staining for both glucagon and PCNA confirmed an increased presence of -cells with evidence of DNA synthesis 8 d after STZ treatment compared with control rats (Fig. 4A). When quantified, the number of -cells per area of pancreas was significantly increased 8 and 12 d after STZ compared with controls (Fig. 4B). On d 8, the percentage of these -cells that also showed nuclear staining for PCNA was 23 ± 2% in control animals, but it was 41 ± 3% was STZ treatment (P < 0.01). Within the same tissue sections, the percentage of ß-cells that also stained for PCNA was 16 ± 3% in controls and 25 ± 4% after STZ (P < 0.05). PCNA labeling was also seen within ductal epithelial cells and was significantly increased in pancreas from STZ-treated rats on 12 d (Fig. 4C).
|
|
-cell presence on the expression of the proglucagon gene and the presence of its products. Circulating glucagon was increased 8 d after STZ treatment, but was no different from control values on d 16 (Fig. 5A). Proglucagon mRNA was quantified by real-time PCR in intact pancreas and was significantly greater in STZ-treated animals between 16 and 40 d (Fig. 5B). The discrepancy between gene expression and circulating glucagon levels prompted the measurement of a second major product of the proglucagon gene, GLP-1. Glucagon and GLP-1 levels were each measured by RIA in extracts from intact pancreata. Both were present on d 4 and 8 after STZ treatment and declined by d 40 (Fig. 6). On d 8, the content of GLP-1 was significantly elevated in STZ-treated animals, whereas that of glucagon was unaltered, resulting in a significant change in the proglucagon gene product ratio in favor of GLP-1.
|
|
) and in the area of pancreas represented by ß-cells (Fig. 7B); this was reduced further in STZ-treated animals. Some animals were followed until 28 d of age and subjected to a glucose tolerance test. GLP-1-(9–39) alone did not alter the glucose excursion profile, but animals receiving STZ had a significantly worse glucose tolerance if they had also received GLP-1-(9–39) (Fig. 7C).
|
). Similarly, mRNA for the GLP-1 receptor, which is present on ß-cells, was also less abundant (Fig. 8B). Visualization of insulin-positive cells within islets of control rats by immunofluorescence on d 8 showed little costaining with GLP-1 or glucagon (Fig. 9), although they did contain the GLP-1 receptor (Fig. 10). However, in pancreata from animals receiving STZ, costaining of insulin with GLP-1 and glucagon was seen (Figs. 9 and 10), especially in small and medium-sized islets, at more than twice the frequency in control rats (Fig. 11). Islet cells from STZ-treated rats, but not controls, also demonstrated colocalization of glucagon with Pdx-1 and of glucagon with Glut-2 (Fig. 12).
|
|
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Loss of ß-cells was rapidly followed by the increased appearance of individual insulin- and glucagon-positive cells associated with pancreatic ducts, although increased labeling of duct epithelium with PCNA was not seen until d 12. This suggests that new endocrine cells appearing within the first 4 d after STZ treatment were derived directly from existing precursors within the ducts. By d 8 after treatment, there was a significantly increased population of smaller islets. This occurred despite a substantial reduction in total volume-weighted mean islet volume and a reduction in the number of larger islets subsequent to ß-cell destruction, and it agrees with the islet neogenic activity reported previously after STZ treatment (35, 36, 37). However, a second likely source of new ß-cells was from within existing islets. By 8 d after STZ treatment, an increased frequency of PCNA staining was seen in both glucagon- and insulin-positive cells. The increase in proliferative activity in glucagon-positive cells coincided with a significant increase in numbers on d 8 and 12. Hyperglycemia and reduced insulin availability are known to cause increased proglucagon gene expression and circulating glucagon (38, 39), but -cell hyperplasia has only previously been reported in extreme models of glucagon loss, such as with deletion of the prohormone convertase-2 (PC2) gene (40). Some -cells showed colocalization of glucagon with either Pdx-1 or Glut2, suggesting the appearance of an immature phenotype of -cell. However, the major feature of this phenotype was a relative shift in proglucagon gene processing toward GLP-1.
GLP-1 has a variety of trophic effects on ß-cells, including enhancement of glucose-stimulated insulin release, stimulation of cell replication, inhibition of cytokine-mediated apoptosis, and ability to promote the replication and differentiation of ß-cell progenitors (41, 42, 43). A homeostatic increase in islet-derived GLP-1 in juxtaposition to ß-cells in damaged islets would be ideally placed to enable ß-cell renewal by increased proliferation of existing cells or from resident precursors. Such a shift in gene product would imply a change in the expression of PCs within -cells. All islet endocrine cell types express PC1/3, whereas -cells express mainly PC2 (44). PC1/3 and PC2 act together at the ß-cell to process proinsulin to insulin, whereas PC2 selectively converts proglucagon to glucagon in the -cell. In intestinal L cells, proglucagon is processed by PC1/3 to form GLP-1, GLP-2, and glicentin (45). Deletion of the PC1/3 gene produces a complex phenotype of postnatal dwarfism with hyperproinsulinemia and a failure to process proglucagon and insulin (46). Disruption of the PC2 gene caused a delay in islet cell differentiation with a prolonged presence of cells coexpressing glucagon and insulin, a cell phenotype not normally seen after embryonic d 13 of development in mice, or glucagon, Pdx-1, and Nkx6.1 (46, 47). A 3-fold increase in the proliferative rate of proglucagon cells occurred in perinatal life, resulting in adult -cell hyperplasia. Increased numbers of smaller islets were also found in the pancreas. Deletion of the PC2 gene resulted in hyperplasia of somatostatin cells (47). The PCs in pancreas changed dramatically as a result of hyperglycemia/hypoinsulinemia. When most ß-cells in the adult rat were deleted using STZ, a much-increased presence of PC1/3, PC2, glucagon, and GLP-1 was reported after 6 d in the remaining islets, whereas GLP-1 levels were increased in pancreas and serum (48). However, the ratio of proinsulin to insulin was unaltered, and the increase in PC2 expression was limited to -cells.
The present studies strongly suggest a change in the relative expression of PC1/3 and PC2 within the -cell population 1–2 wk after STZ treatment. As in the PC2 gene-deleted mouse, we found rapid -cell hyperplasia with evidence of -cell immaturity and a greater appearance of locally produced GLP-1. Because circulating GLP-1 was also elevated, the possibility cannot be excluded that altered processing of the proglucagon gene also occurred in intestinal L cells. These findings suggest that a regenerative plasticity of the ß-cell population in early life involves an ability to modulate proglucagon gene processing and cell number in the adjacent -cells, resulting in the increased local availability of GLP-1. Pancreatic GLP-1 was detected in control animals on postnatal d 8 (4 d after STZ) and declined with age until it was barely detectable by 44 d of age. This is not a direct measure of -cell ontogeny, because substantial acinar cell hyperplasia and hypertrophy occur before weaning in rats, but it indicates that local production of GLP-1 contributes to the developmental remodeling of the islets seen at this time. The abundance in the rat pancreas of the biologically active and processed amidated form of GLP-1 is maximal on postnatal d 8 (49). This GLP-1 is functionally active, because we found that administration of the GLP-1 receptor antagonist, GLP-1-(9–39), caused a reduction in the recovery of ß-cells after STZ and resulted in worse glucose tolerance in these animals. The use of GLP-1-(9–39) was previously shown to be less effective in preventing ß-cell recovery after partial pancreatectomy compared with the phenotype in GLP-1 receptor-null mice (50).
The identity of the target cells for GLP-1 action is unclear. This is likely to include remaining differentiated ß-cells, because the proliferation rate of insulin-positive cells was increased 8 d after STZ, and expression of GLP-1 receptor was present at this time. However, after STZ treatment, an increased number of atypical insulin-positive cells was found in the core of small and medium-sized islets that colocalized both glucagon and GLP-1 receptor. This may reflect differentiation of new endocrine cells from resident precursors (27) or, possibly, dedifferentiation of existing endocrine cells to a proliferative precursor phenotype and subsequent redifferentiation into ß-cells. Similar cells coexpressing insulin and glucagon were also reported after near-total ablation of ß-cells with STZ in neonatal rats (51). Dedifferentiation of islet-derived endocrine cells into cytokeratin-positive epithelial cells expressing c-Kit and/or nestin and their expansion over multiple passages have been reported in vitro (52, 53, 54). These cultures lose expression of all endocrine cell markers, but are able to form pseudoislet structures and reexpress insulin once transferred to a collagen type 4/laminin-rich matrix.
In summary, by inducing ß -cell loss with STZ between birth and weaning, we have documented a rapid regeneration that appears to involve the generation of new islets and the restructuring of preexisting islets. Coincident with ß -cell renewal within islets was a hyperplasia of glucagon-positive cells and a change in proglucagon gene processing to favor GLP-1. This is likely to reflect a homeostatic stimulus to restore ß-cell mass, which may become rate limiting with age.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
The authors have no duality of interest with any company whose products or services are directly linked to the subject matter of this paper.
First Published Online February 16, 2006
Abbreviations: GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; Glut-2, glucose transporter-2; PC, prohormone convertase; PCNA, proliferating cell nuclear antigen; Pdx-1, pancreatic duodenal homeobox-1; STZ, streptozotocin.
Received April 5, 2005.
Accepted for publication February 8, 2006.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100:1438–1443-cell proliferation, and islet neogenesis. Endocrinology 144:4061–4069This article has been cited by other articles:
 |
|
 |
|
  V. Ionut, H. Liu, V. Mooradian, A. V. B. Castro, M. Kabir, D. Stefanovski, D. Zheng, E. L. Kirkman, and R. N. Bergman Novel canine models of obese prediabetes and mild type 2 diabetes Am J Physiol Endocrinol Metab, January 1, 2010; 298(1): E38 - E48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chamson-Reig, S. M. Thyssen, D. J. Hill, and E. Arany Exposure of the Pregnant Rat to Low Protein Diet Causes Impaired Glucose Homeostasis in the Young Adult Offspring by Different Mechanisms in Males and Females Exp Biol Med, December 1, 2009; 234(12): 1425 - 1436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Tan, Y. Feng, Y.-P. Zhou, G. J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, et al. Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice Diabetes, August 1, 2008; 57(8): 2211 - 2219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jin Mechanisms underlying proglucagon gene expression J. Endocrinol., July 1, 2008; 198(1): 17 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Tai, B. Nguyen, R. G. Wells, M. S. Kovacs, R. McGirr, F. S. Prato, T. G. Morgan, and S. Dhanvantari Imaging of Gene Expression in Live Pancreatic Islet Cell Lines Using Dual-Isotope SPECT J. Nucl. Med., January 1, 2008; 49(1): 94 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yano, Z. Liu, J. Donovan, M. K. Thomas, and J. F. Habener Stromal Cell Derived Factor-1 (SDF-1)/CXCL12 Attenuates Diabetes in Mice and Promotes Pancreatic {beta}-Cell Survival by Activation of the Prosurvival Kinase Akt Diabetes, December 1, 2007; 56(12): 2946 - 2957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Georgia and A. Bhushan p27 Regulates the Transition of {beta}-Cells From Quiescence to Proliferation Diabetes, November 1, 2006; 55(11): 2950 - 2956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Wideman, I. L. Y. Yu, T. D. Webber, C. B. Verchere, J. D. Johnson, A. T. Cheung, and T. J. Kieffer Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1) PNAS, September 5, 2006; 103(36): 13468 - 13473. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
) or animals treated with STZ (
) between 2 and 20 d after STZ treatment. Data are derived from 12–18 animals at each time point. *, P < 0.05 or better vs. control.
), STZ (
). Figures represent eight to 10 animals at each time point. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (vs. control). &, P < 0.05 (vs. STZ). C, Glucose values (mean ± SEM) during a glucose tolerance test in animals that had received saline (
